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Abstract
Background: In the biopharmaceutical industry, biomarkers define molecular taxonomies of patients and diseases
and serve as surrogate endpoints in early-phase drug trials. Molecular biomarkers can be much more sensitive than
traditional lab tests. Discriminating disease biomarkers by traditional method such as DNA microarray has proved
challenging. Alternative splicing isoform represents a new class of diagnostic biomarkers. Recent scientific evidence
is demonstrating that the differentiation and quantification of individual alternative splicing isoforms could improve
insights into disease diagnosis and management. Identifying and characterizing alternative splicing isoforms are
essential to the study of molecular mechanisms and early detection of complex diseases such as breast cancer.
However, there are limitations with traditional methods used for alternative splicing isoform determination such as
transcriptome-level, low level of coverage and poor focus on alternative splicing.
Results: Therefore, we presented a peptidomics approach to searching novel alternative splicing isoforms in
clinical proteomics. Our results showed that the approach has significant potential in enabling discovery of new
types of high-quality alternative splicing isoform biomarkers.
Conclusions: We developed a peptidomics approach for the proteomics community to analyze, identify, and
characterize alternative splicing isoforms from MS-based proteomics experiments with more coverage and
exclusive focus on alternative splicing. The approach can help generate novel hypotheses on molecular risk factors
and molecular mechanisms of cancer in early stage, leading to identification of potentially highly specific
alternative splicing isoform biomarkers for early detection of cancer.
Introduction
A biomarker as defined by the National Cancer Institute
is “a biological molecule found in blood, other body
fluids, or tissues that is a sign of a normal or abnormal
process, or of a condition or disease [1].” It is a charac-
teristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic pro-
cesses, or pharmacologic responses to a therapeutic
intervention [2]. The field of biomarkers has grown
extensively over the past decade in many areas such as
medicine, cell biology, genetics, geology and astrobiol-
ogy, and ecotoxicology etc. and biomarkers are currently
being studied in many academic centers and in industry.
In recent years, functional genomics studies using
DNA Microarrays have been shown effective in identify-
ing markers differentiating between breast cancer tissues
and normal tissues, by measuring thousands of differen-
tially expressed genes simultaneously [3-5].
However, early detection and treatment of breast can-
cer is still challenging. One reason is that obtaining tissue
samples for microarray analysis can be still difficult.
Another reason is that genes are not directly involved in
any physical functions. On the contrary, the proteome,
are the real functional molecules and the keys to
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understanding the development of cancer. Moreover, the
fact that breast cancer is not a single homogeneous dis-
ease but consists of multiple disease status, each arising
from a distinct molecular mechanism and having a dis-
tinct clinical progression path [6] makes the disease diffi-
cult to early detect.
Alternative splicing isoforms represent a new class of
diagnostic biomarkers [7]. The chance of success with
alternative splicing isoforms would be higher than the
conventional approach [8,9]. Alternative splicing occurs
in 95% human genes and works by selecting specific
exons and sometimes even intronic regions of the gene
into mature mRNAs [10]. Alternative splicing accounts
for approximately 8% of all protein isoforms which is
any of several different forms of the same protein and
have three types: alternative splicing, SNP, and posttran-
slational modification (PTM).
Recent scientific studies have shown that diseased cells
may produce many types of splicing variants of common
regulatory proteins, e.g., protein kinase C, 14-3-3, p53,
and VGFR, which could provide novel insights into
complex disease diagnosis and management, particularly
in cancers [11-14]. Alternative mRNA splicing is an
important source of achieving molecular functional
diversity. It is often regulated in a temporal or tissue-
specific fashion, giving rise to different protein isoforms
in different tissues or developmental states mediated by
extracellular signaling mechanisms [15,16]. Splicing reg-
ulation is a key mechanism to tune gene expression to a
variety of conditions and its dysfunction may often be at
the basis of the onset of genetic disease and cancer [9].
In cancer, many examples of alternative splicing iso-
forms were reported [17-21]. For example, Julian et al.
used a high-throughput reverse transcription-PCR-based
system for splicing annotation to monitor the alternative
splicing profiles of 600 cancer-associated genes in a
panel of 21 normal and 26 cancerous breast tissues.
They found that 41 alternative splicing events signifi-
cantly differed in breast tumors relative to normal breast
tissues and that most cancer-specific changes in splicing
that disrupt known protein domains support an increase
in cell proliferation or survival consistent with a func-
tional role for alternative splicing in cancer. Compared
to normal mRNA splicing events, alternative splicing
mechanisms and patterns in complex diseases such as
cancer can be quite complex. Finding alternative splicing
isoforms or patterns of their development, therefore,
have been promising in helping develop high-quality
biomarkers and targets for disease management [22].
Discovering disease biomarkers in the human plasma
has been met with both enthusiasm and criticisms in
recent years. On one hand, it is expected that disease
conditions such as cancer may be diagnosed early by ana-
lyzing complex protein mixtures in easily accessible
human blood (serum or plasma), in which proteins
induced by cancer may be differentially cleaved, secreted,
leaked out, and therefore differentially detected from nor-
mal healthy conditions. On the other hand, the bulk of
proteins circulating in human blood vary in different con-
ditions without cancers and across different individuals,
and changes in protein expressions are often diluted in
the blood – extremely challenging for biological interpre-
tation of protein quantification changes [23,24]. The use
of alternative splicing isoforms as potential biomarkers,
therefore, offers a new opportunity to use the detectabil-
ity instead of quantification of biomarker peptides, for
the peptides that may map to unique alternative splicing
isoforms specific to cancer.
However, systematic, comprehensive, proteome-scale
experimental and computational characterization of pro-
tein isoforms directly at the protein/peptide level and
with exclusive focus on alternative splicing has never
been reported. Compared with the “indirect” transcrip-
tome-level characterizations such as EST sequencing
[25], exon array[26], exon-exon junction array[27], and
next-generation sequencing of all mRNA transcripts
[28,29], “direct” proteome-level characterization of alter-
native splicing isoforms can address the wide-spread
concern that mRNA expressions and protein expression
do not correlate well in a clinical proteomics [30,31]. In
2010, we developed the PEPtidomics Protein Isoform
Database (PEPPI [32], http://bio.informatics.iupui.edu/
peppi), a database of computationally-synthesized
human peptides that can identify protein isoforms
derived from either alternatively spliced mRNA tran-
scripts or SNP variations. Although the PEPPI database
is the first peptidomics protein isoform database, it is
not exclusive to alternative splicing and has poor cover-
age of alternative splicing.
Therefore, based on the PEPPI [32], we presented a
new peptidomics approach to searching novel alternative
splicing isoform in proteomics data and demonstrated
that the approach can help researchers identify and
characterize novel alternative splicing isoform from
experimental proteomics data and discover diagnostic
value and clinical significance.
Materials and methods
Human plasma samples
Plasma protein profiles were collected by the Hoosier
Oncology Group (HOG) (Indianapolis, IN, USA). Each
sample was analyzed in a single batch by mass spectro-
metry. In the study, 80 plasma samples were collected
(40 samples collected from women with breast cancer
and 40 from healthy volunteer woman who served as
controls). An independent validation dataset of 80 sam-
ples which contains 40 samples collected from women
diagnosed with breast cancer and 40 from healthy
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volunteer woman who served as controls were collected
by the Hoosier Oncology Group (HOG) (Indianapolis,
IN, USA) too and is comparable to the study in the
demography and clinical distribution of breast cancer
stages/subtypes. For example, most of patients involved
in the two studies were diagnosed with an early stage
breast cancer (stage I or II), fell into age group between
40 and 65, and had mean tumor size of 2.2.
Protein identification and quantification
For protein identification, Tryptic peptides were ana-
lyzed using Thermo-Fisher Scientific linear ion-trap
mass spectrometer (LTQ) coupled with a Surveyor
HPLC system. Peptides were eluted with a gradient
from 5 to 45% Acetonitrile developed over 120 minutes
and data were collected in the triple-play mode (MS
Scan, zoom scan, and MS/MS scan). The acquired raw
peak list data were generated by XCalibur (version 2.0)
using default parameters and further analyzed by the
label-free identification and quantitative algorithm using
default parameters described by Higgs et al [33]. MS
database searches were performed against the combined
protein data set from International Protein Index and
the non-redundant NCBI-nr human protein database,
which totaled 22,180 protein records. Carious data pro-
cessing filters for protein identification were applied to
keep only peptides with the XCorr score above 1.5 for
singly charged peptides, 2.5 for doubly charged peptides,
and 3.5 for triply charged peptides. These XCorr scores
were set according to linear discriminant analysis similar
to that described in DTASelect (version 2.0) to control
false-positive rate at below 5% levels.
For protein quantification, first, all extracted ion chro-
matograms (XICs) were aligned by retention time. Each
aligned peak were matched by precursor ion, charge
state, fragment ions from MS/MS data, and retention
time within a one-minute window. Then, after align-
ment, the area-under-the-curve (AUC) for each indivi-
dually aligned peak from each sample was measured,
normalized, and compared for relative abundance–all as
described in [33]. Here, a linear mixed model general-
ized from individual ANOVA (Analysis of Variance) was
used to quantify protein intensities. In principle, the lin-
ear mixed model considers three types of effects when
deriving protein intensities based on weighted average
of quantile-normalized peptide intensities: 1) group
effect, which refers to the fixed non-random effects
caused by the experimental conditions or treatments
that are being compared; 2) sample effect, which refers
to the random effects (including those arising from sam-
ple preparations) from individual biological samples
within a group; 3) replicate effect, which refers to the
random effects from replicate injections from the same
sample preparation.
Peptidomics approach to searching novel alternative
splicing isoform in proteomics data
Our peptidomics approach to identifying novel alterna-
tive splicing isoform in proteomics data includes three
steps (Figure 1): 1) building an synthetic database of
Figure 1 A peptidomics approach to identifying novel alternative splicing isoforms in proteomics data.
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alternative splicing isoforms for proteomics experiments;
2) identification, characterization of alternative splicing
isoform using proteomics; and 3) validation of alterna-
tive splicing isoform.
Step 1: building a synthetic database of alternative
splicing isoforms for proteomics experiments
Briefly, we developed the Synthetic Alternative Splicing
Database (SASD) [34] in three steps: 1)extracting infor-
mation on gene structures of all genes in the human
genome and incorporating the IPAD database [35], 2)
compiling artificial splicing transcripts, and 3) translat-
ing the artificial transcripts into alternative splicing
peptides.
In the first step, we use the BioMart to extract infor-
mation on all human genes in the Ensemble [36] from
the Homo sapiens genes dataset (GRCh37.p10) in the
Ensembl Genes 71 database. We then extract informa-
tion on each human gene’s position, name, exon/intron
coordinates, exon phase, sequences, and annotation.
In the second step, we generate artificial splicing tran-
script (AST), which is an exhaustive compilation of two
categories of peptides. The first category is the peptides
translated from all single exons and introns, and the
second category is the peptides that cover all theoreti-
cally possible exon/intron junction regions of all genes
in the human genome. The first category contains two
types of alternative splicing: single exon(EXON_NM)
and single intron (INTRON_AS). The second category
contains four types of alternative splicing: intron-exon
(I_E_AS, left intron retention junction), exon-intron
(E_I_AS, right intron retention junction), neighboring
exon-exon (E_E_NM, normal splicing junction) and
non-neighboring exon-exon (E_E_AS, exon skipping
junction).
In the third step, we directly use the phase to translate
the sequence for the exons with the phase information
in Ensemble transcript. For the exons without the phase
information in Ensemble transcript, three open reading
frames are used in translating into three peptides and
the longest peptide crossing the splicing site is reserved
as alternative splicing peptide for SASD.
Step 2: identification and characterization of alternative
splicing isoform using proteomics
The most popular three types of search algorithms are
1) correlating acquired MS/MS with theoretical spec-
trum, counts the number of peaks in common, such as:
SEQUEST [37] and X!Tandem [38], 2) modeling the
extent of peptide fragmentation, then estimates the
probability that an assignment is incorrect due specifi-
cally to a random match, such as Mascot [39] and
OMSSA [40], and 3) De Novo Sequencing such as Lute-
fisk[41] and PEAKS[42]. We first run OMSSA against
SASD to identify peptide from MS data. Then we per-
form preliminary data analysis. Last, we extract informa-
tion about alternative splicing.
OMSSA reports hits ranked by E-value. An E-value
for a hit is a score that is the expected number of ran-
dom hits from a search library to a given spectrum,
such that the random hits have an equal or better score
than the hit. For example, a hit with an E-value of 1.0
implies that one hit with a score equal to or better than
the hit being scored would be expected at random from
a sequence library search [40]. The E-value is calculated
to report the expected frequency of observing scores
equivalent to or better than the one for the reported
peptide if the results were to take place randomly. The
lower the E-value is, the more significant the score for
the identified peptide by the peptide search using SASD
database is.
One-sided Wilcoxon signed-rank test is used to per-
form the preliminary statistical analysis in order to iden-
tify peptides with significant occurrence differences in
the health and breast cancer samples.
Step 3: validation of alternative splicing isoform
We present two kinds of methods to validate isoforms
in proteomics data, which are 1) literature curation of
alternative splicing isoforms and 2) cross-validation of
multiple studies. First, we perform an extensive litera-
ture curation to determine the constituents of alterna-
tive splicing isoform. Then, we validate results using
independent proteomics datasets derived from other
study. We believe that such an integrative systems
approach is essential to development and validation of
panel alternative splicing isoform that may withstand
rigorous testing for the future steps.
Pathway analysis
Pathway analysis is performed using the following data-
bases: Integrated Pathway Analysis Database (IPAD)
(http://bioinfo.hsc.unt.edu/ipad/) [43].
Results
The 80 breast cancer plasma samples with 40 samples
from women diagnosed with breast cancer and 40 from
healthy volunteer women as controls were searched by
OMSSA[40] against the SASD database. After OMSSA
searching, preliminary statistical analysis, and alternative
splicing, we identified the eight alternative splicing iso-
form biomarkers using the peptidomics approach to
searching novel alternative splicing isoform in the proteo-
mics data (Table 1). The peptides with E-value greater
than 0.01 were filtered out. The P-value was calculated
by performing one-sided Wilcoxon signed-rank test to
examine the probability that the median difference
between two groups of samples is greater than zero. The
number of such peptide found in Health (h) and Cancer
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(c) samples are listed separately in the table. The tested
peptides are more likely to exist in cancer samples than
in healthy samples when P-value is small. Bold text is the
left part of the junction and italic text is the right part.
Splicing site is marked by ^ or (). ‘()’ means the splicing
site is shared by the left region and right region. For
example, the second peptide QTPKHISESLGAEVDP
DMSWSSSLATPPTLSSTVLI(G)LLHSSVK is a synthetic
product of the ENST00000380152 in gene BRCA2 when
its eighth, ninth, and tenth exons are skipped and its
seventh exon is combined together with its eleventh
exon. The Glycine is the shared splicing site between the
seventh exon and the eleventh exon.
None of the eight peptides are reported to have ever
been detected in the Peptide Atlas database, which con-
tains a comprehensive catalogue of all peptides derived
from published proteomics experiments. They are not
found with normal splicing mechanism (Table 1).
The first sequence is a single intron alternative spli-
cing. It was observed in 20 patient samples and 4
healthy samples. Triple play mode of the annotated
Thermo-Finnegan LCQ-DECA ion-trap MS/MS spec-
trum is shown in Figure 2[44]. The triple play mode
includes a) primary mass spectrum; b) zoom scan mass
spectrum; c) MS/MS mass spectrum and d) protein
identification from MS/MS). Due to space limit, the
spectrums of other seven alternative splicing sequences
are omitted.
The eight peptides, identified by OMSSA, have signifi-
cant difference in the numbers of hit samples between
healthy women and breast cancers (pvalue < 0.05, Table
1). A screen shot from the UCSC genome browser [45]
in the region of these peptides are also shown in Figure
3. It shows that these peptide sequences are not found
in EST sequences and mRNA from Genbank and one
refseq gene(Figure 3).
Table 1 shows that our peptidomics approach has sig-
nificant potential in enabling discovery of new types of
high-quality alternative splicing isoform biomarkers.
Further literature search found that there are no any lit-
erature reports for the eight peptides. Moreover, a
cross-validation found that identification of the eight
peptides is supported by the independent Study which
contains 40 samples collected from women diagnosed
with breast cancer and 40 from healthy volunteer
woman who served as controls.
Pathway analysis shows the pathways linked with the
eight alternative splicing isoforms are transcription fac-
tor, signaling, cancer, and synthesis (Table 2).
Discussions
We described the peptidomics approach to searching
novel alternative splicing isoform in proteomics data,
especially artificial alternative splicing and SNP. We can
use it to identify two types of common alternative spli-
cing events: Exon Skipping and Intron Retention. Exon
Skipping is an alternative splicing mechanism in which
exon(s) are included or excluded from the final gene
transcript leading to extended or shortened mRNA var-
iants. And Intron Retention is an event in which an
intron is retained in the final transcript. Other types of
alternative splicing events such as alternative 3’ splice
site and 5’ splice site are not included in our method
but can be derived indirectly from the two basic types:
exon skipping and intron retention.
The current protein sequence databases used by tan-
dem mass spectra search engines, for example IPI, Uni-
Prot, and NCBI nr, are designed to be useful as possible
to as many researchers as possible. As such, they are a
less than ideal substrate for tandem mass spectra search.
Protein sequence databases typically represent only
“full-length” protein sequences and attempt to collapse
protein variants to a single “consensus” entry. Tandem
mass spectra search engines, however, chop up the pro-
tein sequence using an in-silico enzymatic digestion
(such as trypsin), so full-length proteins are not needed
in order to identify experimentally observed peptides;
and the currently available search engines require the
experimental peptides’ sequences be explicitly present in
the sequence database in order to identify them, so
explicit sequence variants are very important. The SASD
is in fact a complete peptide sequence database, which
Table 1 Novel alternative splicing isoform candidate biomarkers for breast cancer in plasma
Peptide sequence gene transcript mode type pvalue h c Peptide
Atlas
SWGGRPQRMGAVPGGVWSAVLMGGAR ERBB2 ENST00000269571 i18 INTRON_AS 9.48E-05 4 20 No
QTPKHISESLGAEVDPDMSWSSSLATPPTLSSTVLI(G)LLHSSVK BRCA2 ENST00000380152 E7_E11 E_E_AS 8.57E-04 1 12 No
SLWLQSQPHFCCFWLTVTFPPPLQ^THRELAQSSHAQR NTRK3 ENST00000317501 i2_E3 i_E_AS 1.22E-02 2 10 No
WGLLLALLPPGAASTQ(A)VWTWMTR ERBB2 ENST00000269571 E1_E16 E_E_AS 1.22E-02 2 10 No
LSWNHVARALTLTQSLVSSVTSGK NTRK3 ENST00000559764 i2 INTRON_AS 1.39E-02 4 13 No
CQ(G)EPYHDIRFNLMAVVPDR BAP1 ENST00000460680 E3_E9 E_E_AS 3.33E-02 9 18 No
QVLP^VGVLGPPGQQAPPPYPGPHPAGPPVIQQPTTPMFVAPPPK PBRM1 ENST00000296302 E9_E29 E_E_AS 3.89E-02 6 14 No
DHLACW^DYDLCITCYNTKNHDHK EP300 ENST00000263253 E22_E31 E_E_AS 4.50E-02 4 11 No
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Figure 2 Triple play mode spectrum of SWGGRPQRMGAVPGGVWSAVLMGGAR in patient C_024.
Figure 3 UCSC genome browser screen shot of genomic region for the novel peptide.
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Table 2 Pathway analysis for the eight alternative splicing isoforms.
PathwayID PathwayName Molecule
200017 p73 transcription factor network BRCA2;EP300
200141 FOXM1 transcription factor network EP300;BRCA2
200200 Validated targets of C-MYC transcriptional repression EP300;ERBB2
hsa04520 Adherens junction ERBB2;EP300
hsa05212 Pancreatic cancer ERBB2;BRCA2
1306955 GRB7 events in ERBB2 signaling ERBB2
1358803 Downregulation of ERRB2:ERBB3 signaling ERBB2
168253 Host Interactions with Influenza Factors PBRM1
168268 Virus Assembly and Release PBRM1
168270 Fusion and Uncoating of the Influenza Virion PBRM1
168275 Entry of Influenza Virion into Host Cell via Endocytosis PBRM1
168303 Packaging of Eight RNA Segments PBRM1
168330 Viral RNP Complexes in the Host Cell Nucleus PBRM1
192814 vRNA Synthesis PBRM1
192869 cRNA Synthesis PBRM1
200159 ErbB receptor signaling network ERBB2
168277 Influenza Virus Induced Apoptosis PBRM1
168288 Fusion of the Influenza Virion to the Host Cell Endosome PBRM1
168298 Release PBRM1
168302 Budding PBRM1
168336 Uncoating of the Influenza Virion PBRM1
192905 vRNP Assembly PBRM1
73951 Homologous recombination repair of replication-independent double-strand breaks BRCA2
918233 TRAF3-dependent IRF activation pathway EP300
73888 Homologous Recombination Repair BRCA2
76003 Presynaptic phase of homologous DNA pairing and strand exchange BRCA2
76010 Homologous DNA pairing and strand exchange BRCA2
h_hifPathway Hypoxia-Inducible Factor in the Cardiovascular System EP300
h_pitx2Pathway Multi-step Regulation of Transcription by Pitx2 EP300
h_ppargPathway Role of PPAR-gamma Coactivators in Obesity and Thermogenesis EP300
h_RELAPathway Acetylation and Deacetylation of RelA in The Nucleus EP300
hsa05200 Pathways in cancer ERBB2;BRCA2;EP300
h_carm1Pathway Transcription Regulation by Methyltransferase of CARM1 EP300
h_melanocytepathway Melanocyte Development and Pigmentation Pathway EP300
h_pelp1Pathway Pelp1 Modulation of Estrogen Receptor Activity EP300
h_vdrPathway Control of Gene Expression by Vitamin D Receptor EP300
hsa05215 Prostate cancer ERBB2;EP300
h_il7Pathway IL-7 Signal Transduction EP300
168325 Viral Messenger RNA Synthesis PBRM1
1963640 GRB2 events in ERBB2 signaling ERBB2
419524 Fanconi Anemia pathway BRCA2
73890 Double-Strand Break Repair BRCA2
416572 Sema4D induced cell migration and growth-cone collapse ERBB2
h_g2Pathway Cell Cycle: G2/M Checkpoint EP300
h_mef2dPathway Role of MEF2D in T-cell Apoptosis EP300
h_atrbrcaPathway Role of BRCA1, BRCA2 and ATR in Cancer Susceptibility BRCA2
h_her2Pathway Role of ERBB2 in Signal Transduction and Oncology EP300
h_nthiPathway NFkB activation by Nontypeable Hemophilus influenzae EP300
h_p53hypoxiaPathway Hypoxia and p53 in the Cardiovascular system EP300
h_tgfbPathway TGF beta signaling pathway EP300
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includes majority of all occurrence of alternative spli-
cing. It also provides alternative splicing for each pep-
tide, such as splicing mode, splicing type, splicing site,
starting position, ending position, and peptide sequence.
Moreover, the current protein sequence databases and
some alternative splicing database such as ASTD and
EID are not ideal or enough for identifying alternative
splicing isoform from tandem mass spectrometry. There
are either no or very few isoform information in these
databases. For example, ASTD only includes 9757
occurrences of intron isoforms and 5214 occurrences of
exon isoforms. Even for Cassette exons event, the num-
ber of occurrences is only 12470[15]. In contrast, the
SASD database in our method includes 11,919,779
Alternative Splicing peptides covering about 56,630
genes (ensembl gene IDs), 95,260 transcripts (ensembl
transcript IDs), 1956 pathways, 6704 diseases, 5615
drugs, and 52 organs.
Its comprehensive coverage means better sensitivity in
identifying novel alternative splicing isoforms than the
PEPPI. And its exclusive focus on alternative splicing
can definitely increase the specificity of the identification
of alternative splicing.
Alternative splicing isoform biomarkers are apparently
important and can serve as an alternative to traditional bio-
markers. We can use quantitative information such as p-
value to determine the significance of the marker. We can
also use the qualitative information such as: splicing type,
splicing mode, peptide sequence etc. to further analyze the
alternative splicing’s mechanism. We think that combina-
tion of traditional biomarkers with the alternative splicing
isoform biomarkers will definitely help us better under-
stand the treatment, diagnosis, and prognosis of cancer.
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